Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Rhea-AI Summary

Werewolf Therapeutics, Inc. (HOWL) announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at the Evercore ISI HealthCONx Conference. The company is known for developing conditionally activated therapeutics to stimulate the immune system for cancer treatment. The event will take place on November 29, 2023, in Miami, Florida, with a live webcast link available on the company's investor relations website.

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.

A live webcast link for the Evercore ISI HealthCONx Conference presentation will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.

About Werewolf Therapeutics:

Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma.

Investor Contact:
Josh Rappaport Stern IR 212.362.1200
Josh.Rappaport@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications 301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer Werewolf Therapeutics
elubman@werewolftx.com

FAQ

When will the fireside chat at the Evercore ISI HealthCONx Conference take place for Werewolf Therapeutics, Inc. (HOWL)?

The fireside chat is scheduled for 8:20 AM ET on November 29, 2023.

Who will participate in the fireside chat for Werewolf Therapeutics, Inc. (HOWL) at the Evercore ISI HealthCONx Conference?

Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will participate in the fireside chat.

Where can I access the live webcast link for the Evercore ISI HealthCONx Conference presentation by Werewolf Therapeutics, Inc. (HOWL)?

The live webcast link will be available at https://investors.werewolftx.com/news-and-events/events.

How long will the archived replay of the Evercore ISI HealthCONx Conference presentation by Werewolf Therapeutics, Inc. (HOWL) be available?

The archived replay will be available for approximately 90 days following the event.